Intuitive Surgical (ISRG) is currently trading at its lowest valuation in the past decade, with a forward 12-month P/E of 30.26X, significantly below its 10-year median of 58.18X. This decline of over 40% from a January peak of $600 reflects investor concerns over moderating U.S. procedure trends and competition in China. Despite strong growth, including a 19% year-over-year revenue increase to $2.89 billion in Q2 2026, investors have shown caution.
Management has maintained its 2026 growth forecast for da Vinci procedures at 13.5-15.5%, driven by demand in general and surgical specialties. The company reported a utilization increase of 3% for da Vinci and 11% for Ion systems, with total procedures rising 16%. Although Intuitive Surgical has raised its adjusted gross-margin outlook to 68-69%, challenges such as higher costs and market pressures remain evident as the company transitions to new platforms.
In the second quarter, Intuitive Surgical installed 468 da Vinci systems and 55 Ion systems, showing continued product innovation. However, ISRG shares have dropped 15% over the last three months, underperforming both the Zacks Medical – Instruments industry’s 10% growth and the broader Medical sector’s 9.6% increase. Investors should weigh current growth against potential pressures before making decisions on their holdings.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
